Barcelona – January 24, 2025 – 52Platform, a leader in neuroscientific innovation, has announced Bleuler, a groundbreaking project to develop a platform designed to transform the treatment of schizophrenia. Engineered with the most advanced capabilities of artificial intelligence, Bleuler aims to provide personalized solutions based on precise data. This international project involves collaboration with Synaptia Health Group in Spain, MJN Neuro, the National Institute of Neurology and Neurosurgery “Manuel Velasco Suárez” in Mexico, and Rey Juan Carlos University.

Schizophrenia affects over 25 million people worldwide. This disorder presents significant challenges due to variability in patient responses to current treatments. Bleuler, still in the study phase, focuses on developing an innovative clinical approach that combines electroencephalographic biomarkers and advanced cognitive assessments through artificial intelligence.

“Bleuler has the potential to revolutionize the medical care of schizophrenia”, stated Adrián Trejo de la Rosa, CEO and co-founder of 52Platform. “This project is a step towards more precise treatment that will improve the quality of life for patients and provide doctors with reliable technological tools for making critical decisions. Our vision does not stop here; we want to expand this model to other neurological disorders and continue leading the future of personalized medicine”.

The development of Bleuler will be possible thanks to a grant of 973,811.33 Euros from a total budget of 1,604,067 Euros, awarded by the Center for Technological Development and Innovation (CDTI), a Public Business Entity under the Ministry of Science, Innovation, and Universities. This funding, as part of its program to support high-impact R&D projects, will allow progress in research, validate the technology, and refine the platform’s design.

Technological Innovation at the Service of Patients

Bleuler seeks to detect early clinical changes in patients and adjust treatments according to their individual needs. Current studies include the development of wearable devices capable of monitoring brain activity from home, combined with automated cognitive analysis systems. These tools are designed to improve the quality of care and reduce unnecessary hospitalizations.

The project is expected to be ready for implementation in November 2026. This goal reinforces the collaborators’ commitment to offering a solution that optimizes the treatment of schizophrenia in both public and private institutions. Besides the clinical impact, Bleuler aims to improve the sustainability of the healthcare system in the long term by reducing costs associated with prolonged treatments. Although the platform is still under development, the projected advancements promise significant benefits for patients and health systems alike.

“Bleuler marks the beginning of a new era in personalized medicine”, concluded Trejo de la Rosa. “We are committed to developing innovative solutions that not only transform the treatment of schizophrenia but also set new standards for other complex disorders”.

Media Contact
Company Name: 52Platform
Contact Person: Press Office
Email: Send Email
Country: United States
Website: https://www.52platform.com/